Benefit-Risk management across
the pharma product lifecycle.
A structured methodology for Benefit-Risk assessment.
The need for structured Benefit-Risk governance and assessment processes is increasing as pharma companies seek to navigate regulatory landscapes, bring products to market more efficiently, and of course ensure patient safety.
Increasingly, it makes sense to consider a product’s Benefit-Risk profile much earlier on in the product lifecycle, when you are trying to optimize the benefits and position risks of the product to maximize the chances of authorization.